Related Experiment Video
Updated: Apr 11, 2026
Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Research progress in corneal cross-linking agents
Abstract:
Corneal collagen cross-linking with UVA-riboflavin is currently the only method for preventing the progression of keratoconus from the pathological perspective. Topical application of a direct cross-linking agent is now attracting widespread attention in clinical settings. This article reviews the research progress in the application of indirect or direct cross-linking agents (e.g., riboflavin, glucose, ribose, glutaraldehyde, formaldehyde, glyceraldehyde, short chain aliphatic β-nitro alcohol, and genipin) in the treatment of corneal diseases and analyzes the cross-linking efficacy, toxicity, and merits and disadvantages of each cross-linking agent, providing clinical information for further studies.
Insights
Corneal collagen cross-linking using UVA-riboflavin is the sole method to halt keratoconus progression. This review examines various cross-linking agents for corneal disease treatment, evaluating their efficacy and safety.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Corneal Disease Research
Background:
- Keratoconus progression is currently only preventable via UVA-riboflavin corneal collagen cross-linking.
- Topical cross-linking agents are gaining clinical interest for treating corneal diseases.
Purpose of the Study:
- To review research on indirect and direct cross-linking agents for corneal disease treatment.
- To analyze the efficacy, toxicity, and comparative advantages/disadvantages of various cross-linking agents.
Main Methods:
- Literature review of studies on corneal cross-linking agents.
- Analysis of cross-linking efficacy, toxicity, and clinical merits/demerits.
- Inclusion of agents like riboflavin, glucose, ribose, glutaraldehyde, formaldehyde, glyceraldehyde, short chain aliphatic β-nitro alcohol, and genipin.
Main Results:
- UVA-riboflavin is the established standard for keratoconus.
- Various agents show potential but require further investigation regarding efficacy and safety profiles.
- Comparative analysis highlights specific strengths and weaknesses of each agent.
Conclusions:
- Cross-linking agents offer promising therapeutic avenues for corneal diseases beyond keratoconus.
- Further research is needed to optimize agent selection and application protocols for clinical use.
- This review provides essential data for guiding future clinical studies and therapeutic development.
More Related Videos
12:25Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
Published on: January 6, 2018
05:56Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
